

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
5 March 2009 (05.03.2009)

PCT

(10) International Publication Number
WO 2009/026717 A1

(51) International Patent Classification:

C07D 495/04 (2006.01) A61P 27/02 (2006.01)
A61K 31/00 (2006.01) A61P 35/00 (2006.01)
A61K 31/4365 (2006.01) A61P 9/00 (2006.01)

(21) International Application Number:

PCT/CA2008/001538

(22) International Filing Date: 28 August 2008 (28.08.2008)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/968,673 29 August 2007 (29.08.2007) US

(71) Applicant (for all designated States except US):
METHYLGENE INC. [CA/CA]; 7220 Frederick-Banting, Si-laurent, Québec H4S 2A1 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CLARIDGE, Stephen William** [CA/CA]; #2, 443 Notre Dame East, Montreal, Québec H2Y 1C9 (CA). **ISAKOVIC, Ljubomir** [CA/CA]; 252 Castle Road, Beaconsfield, Québec H9W 2W5 (CA). **MANNION, Michael** [CA/CA]; 74 St-Cuthbert Street, Montreal, Québec H2W 1L5 (CA). **RAEPPPEL, Stéphane** [CA/CA]; 2620 de l'Étrier, St-lazare, Québec J7T 3L8 (CA). **SAAVEDRA, Oscar Mario** [CA/CA]; 749 Ave. Outremont, Montreal, Québec H2V 3N2 (CA). **GAUDETTE, Frédéric** [CA/CA]; 1880 du Portage, Laval, Québec H7Y 0A2 (CA). **ZHAN, Lijie** [CA/CA]; 2540 Boulevard de la Cote Vertu, Montreal, Québec H4R 1P5 (CA). **ZHOU, Nancy Z.** [CA/CA]; 104 Kirkland

Blvd., Kirkland, Québec H9J 1N9 (CA). **RAEPPPEL, Franck** [FR/CA]; 3194 Claude Jodoin Street, Montreal, Québec H1Y 3M2 (CA). **DÉZIEL, Robert** [CA/CA]; 546 Chester Avenue, Mont-royal, Québec H3R 1W9 (CA). **VAISBURG, Arkadii** [CA/CA]; 10 Riverwood Grove, Kirkland, Québec H9J 2X2 (CA). **UNO, Tet-suyuki** [JP/JP]; c/o Otsuka Pharmaceutical Co., Ltd., 1-7-1 Doshomachi, Chuo-Ku, Osaka-shi, Osaka 541-0045 (JP).

(74) Agent: **BERESKIN & PARR**; 40th Floor, 40 King Street West, Toronto, Ontario M5H 3Y2 (CA).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— with international search report

(54) Title: INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY



M



(57) Abstract: The invention relates to compounds of Formula (I) and their use for inhibiting protein tyrosine kinase activity. In Formula (I), the group M is thieno[3,2-b]pyridinyl as shown, and the group D is a ring or ring system, and the groups Z, Ar, and G are as defined herein. The invention relates particularly to compounds that inhibit the protein tyrosine kinase activity of

growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions, such as cancer, and for treating ophthalmic diseases, including age-related macular degeneration (AMD) and diabetic retinopathy (DR).